Welcome to LookChem.com Sign In|Join Free

CAS

  • or

32725-05-6

Post Buying Request

32725-05-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

32725-05-6 Usage

Aromatic alcohol derivative

This indicates that the compound is based on an aromatic ring (naphthalene) and contains an -OH group, making it an alcohol.

Naphthalene ring

This is the core structure of the compound, which is a fused ring system consisting of two benzene rings.

Methoxy group at the 6-position

This indicates that a -OCH3 group is attached to the naphthalene ring at the 6th position (the second position from the end of the molecule).

Ethyl group at the 2-position

This indicates that a -CH2CH3 group is attached to the naphthalene ring at the 2nd position (the first position from the end of the molecule).

Used as an intermediate in the synthesis of organic compounds

This indicates that the compound is commonly used in the pharmaceutical and chemical industries as a building block for the creation of other organic compounds.

Used as a building block in the creation of complex molecules

This indicates that the compound is an important tool for organic chemists in the creation of more complex molecules.

Potential applications in medicinal chemistry

This suggests that the compound may have potential uses in the development of new drugs and pharmaceuticals.

Check Digit Verification of cas no

The CAS Registry Mumber 32725-05-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,2,7,2 and 5 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 32725-05:
(7*3)+(6*2)+(5*7)+(4*2)+(3*5)+(2*0)+(1*5)=96
96 % 10 = 6
So 32725-05-6 is a valid CAS Registry Number.

32725-05-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-(6-methoxynaphthalen-2-yl)ethanol

1.2 Other means of identification

Product number -
Other names 2-Naphthaleneethanol,6-methoxy

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:32725-05-6 SDS

32725-05-6Relevant articles and documents

Electron transfer processes in the reactivity of nonsteroidal anti-inflammatory drugs in the ground and excited states.

Moore,Ghebremeskel,Chen,Wong

, p. 685 - 691 (1998)

The nonsteroidal anti-inflammatory drugs (NSAID), naproxen, sulindac and indomethacin, were shown to donate electrons to nitro blue tetrazolium (NBT) when irradiated with UV light in deoxygenated aqueous buffer solution (pH 7.4, 30 degrees C). The reaction was monitored spectrophotometrically by the appearance of the diformazan reduction product from NBT. The electron transfer process facilitates the decomposition of the drugs. Naproxen in the presence of NBT is photodegraded principally to the alcohol (2-[1-hydroxyethyl]-6-methoxynaphthalene) at a rate approximately 20-fold faster than when irradiated alone in deoxygenated conditions. The photoproduct from naproxen also participates in the electron transfer to NBT but at a much slower rate than naproxen. Irradiation of sulindac or indomethacin in the presence of NBT caused the slow photoreduction of NBT to diformazan. In the absence of NBT, indomethacin and sulindac are essentially unreactive when irradiated in aqueous solution. The ability of a number of NSAID to act as electron donors in their ground state was studied by observing their oxidation by potassium peroxodisulfate in pH 7.0 phosphate buffer at 50 degrees C. The HPLC analysis of the drug remaining showed that the 2-arylpropionic acid NSAID (naproxen, ibuprofen, ketoprofen and suprofen) reacted at a rate equivalent to the thermal decomposition of peroxodisulfate. The major products were the same as detected in the photooxidation of these drugs, resulting from decarboxylation and oxygen addition but also included a dimeric compound. On the other hand, the NSAID that do not contain the propionic acid substituent all reacted more slowly with peroxodisulfate, enabling specific reaction rate constants to be evaluated.

Baeyer-Villiger Monooxygenase FMO5 as Entry Point in Drug Metabolism

Fiorentini, Filippo,Romero, Elvira,Fraaije, Marco W.,Faber, Kurt,Hall, Mélanie,Mattevi, Andrea

, p. 2379 - 2387 (2017/09/22)

Flavin-containing monooxygenases (FMOs) are emerging as effective players in oxidative drug metabolism. Until recently, the functions of the five human FMO isoforms were mostly linked to their capability of oxygenating molecules containing soft N- and S-nucleophiles. However, the human FMO isoform 5 was recently shown to feature an atypical activity as Baeyer-Villiger monooxygenase. With the aim of evaluating such an alternative entry point in the metabolism of active pharmaceutical ingredients, we selected and tested drug molecules bearing a carbonyl group on an aliphatic chain. Nabumetone and pentoxifylline, two widely used pharmaceuticals, were thereby demonstrated to be efficiently oxidized in vitro by FMO5 to the corresponding acetate esters with high selectivity. The proposed pathways explain the formation of a predominant plasma metabolite of pentoxifylline as well as the crucial transformation of the pro-drug nabumetone into the pharmacologically active compound. Using the recombinant enzyme, the ester derivatives of both drugs were obtained in milligram amounts, purified, and fully characterized. This protocol can potentially be extended to other FMO5 candidate substrates as it represents an effective and robust bench-ready platform applicable to API screening and metabolite synthesis.

THERAPEUTIC PROSTAGLANDIN RECEPTOR AGONISTS

-

Paragraph 0131, (2015/12/30)

Described herein are compounds which can be used in topical liquids, creams, or other dosage forms such as solids, for reducing intraocular pressure, treating glaucoma, growing hair, treating wounds, or other medical and/or cosmetic uses.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 32725-05-6